First of its kind Medication Shows Promise for Diabetic Liver Disease Patients
Larry Greenblatt, MD
Metabolic dysfunction-associated steatotic liver disease (MASLD), once known as non-alcoholic fatty liver disease, affects nearly one in four adults in the United States. This disease can lead to liver scarring and even liver failure, making it a top reason for liver transplants. However, as of early 2024, there aren't any approved medications for treating this disease. But there's good news! Researchers are working on a promising new drug called resmetirom that could change that.
Resmetirom was originally developed to lower bad lipids like cholesterol in the body. Soon, scientists and doctors saw its potential to address the underlying metabolic issues of MASLD. This could help prevent the disease from worsening to fibrosis, a kind of liver scarring, and other serious problems. A recent large study involving nearly 1,000 patients showed that resmetirom could improve liver fibrosis and keep the disease from progressing. This is a big deal because it was achieved in just one year, much faster than expected.
Patients with MASLD often have lipid imbalances not just in their livers but throughout their bodies, leading to a higher risk of heart disease. The study found that resmetirom not only helps with liver health but also improves overall lipid levels. This dual benefit pleased researchers, as about two-thirds of the patients had positive results with the medication. This could mean fewer heart problems and other complications for these patients in the future.
The safety of resmetirom is another highlight. Unlike some previous drugs tested for MASLD, which had severe side effects, resmetirom is well-tolerated. Patients take it once daily as a pill, which is much simpler and has fewer side effects compared to treatments for other serious conditions like cancer.
Looking ahead, the FDA has a fast-track approval process for new treatments like resmetirom that show significant benefits. The results from the study are very encouraging, and doctors are hopeful that they can start prescribing this drug soon. They plan to use it primarily in specialist settings, where they can also offer comprehensive care with dietitians and endocrinologists to support patients.
In conclusion, while diet and lifestyle changes remain essential for managing MASLD, the development of resmetirom offers new hope. It's especially important for identifying and treating patients who don't yet show symptoms of the disease. With continued research and hopefully FDA approval, resmetirom could soon help millions of people with MASLD live healthier lives.
Link to the news story.
Link to the journal article.